Current Report Filing (8-k)
March 26 2020 - 8:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 25, 2020
DELMAR PHARMACEUTICALS, INC.
|
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
001-37823
|
|
99-0360497
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
|
|
|
|
12707 High Bluff Dr., Suite 200
San Diego, CA 92130
(Address of principal executive offices)(Zip
Code)
Registrant’s telephone number,
including area code: (858) 350-4364
Not Applicable
|
(Former name or former address, if changed
since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
DMPI
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On March 25, 2020, DelMar Pharmaceuticals, Inc.
(the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Capital Market LLC
(“Nasdaq”) confirming the Company’s eligibility for continued listing of its common stock on Nasdaq pursuant
to an extension through September 21, 2020, subject to the condition that the Company shall have demonstrated a closing bid price
of $1.00 per share, or more, for a minimum of ten consecutive business days by September 21, 2020. In order to meet such compliance
of the $1.00 per share bid price, we may need to consummate a reverse stock split in order to achieve such stock price.
There can be no assurance that the Company will
be able to regain compliance and if we are unable to regain compliance with the minimum closing bid price requirement by September
21, 2020, or if we fail to meet any of the other continued listing requirements, our securities may be delisted from Nasdaq, which
could reduce the liquidity of our common stock materially and result in a corresponding material reduction in the price of our
common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable
to us, or at all, and may result in the potential loss of confidence by investors, employees and business development opportunities.
Such a delisting likely would impair your ability to sell or purchase our common stock when you wish to do so. Further, if we were
to be delisted from Nasdaq, our common stock may no longer be recognized as a “covered security” and we would be subject
to regulation in each state in which we offer our securities. Thus, delisting from Nasdaq could adversely affect our ability to
raise additional financing through the public, or private sale of equity securities, would significantly impact the ability of
investors to trade our securities, and would negatively impact the value and liquidity of our common stock.
On March 26, 2020, the Company issued a press
release announcing that the Company’s request for continued listing had been granted. A copy of the press release is filed
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DELMAR PHARMACEUTICALS, INC.
|
|
|
Date: March 26, 2020
|
By:
|
/s/ Scott Praill
|
|
|
Name: Scott Praill
Title: Chief Financial Officer
|
Kintara Therapeutics (PK) (USOTC:DMPWW)
Historical Stock Chart
From May 2024 to Jun 2024
Kintara Therapeutics (PK) (USOTC:DMPWW)
Historical Stock Chart
From Jun 2023 to Jun 2024